Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the effectiveness ...
Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 ...
LOS ANGELES--(BUSINESS WIRE)--Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608’s phase 1/2 trial data demonstrates higher response rates ...
The MarketWatch News Department was not involved in the creation of this content. - Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic ...
Alumis Inc., a clinical stage biopharmaceutical company, announced that it will present data on its oral therapy A-005, a selective TYK2 inhibitor, at the ACTRIMS Forum 2025 on February 28, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results